Azenta, Inc. reported fourth‑quarter and full‑year fiscal 2025 results on November 21, 2025, with revenue rising 6% year‑over‑year to $159.2 million from $151 million in Q4 2024 and $594.0 million for the year from $573 million in 2024. The growth reflects a 2% increase in Sample Management Solutions revenue to $86.0 million and an 11% jump in Multiomics revenue to $73.0 million, compared with $85 million and $66 million in the same quarter of 2024.
The company’s adjusted EBITDA expanded to $21.0 million in Q4, a 29% increase from $16.2 million in Q4 2024, and to $66.0 million for the year, up 44% from $46.5 million in 2024. Adjusted EBITDA margins grew to 13.0% in the quarter and 11.2% for the year, driven by a higher mix of high‑margin Multiomics contracts, disciplined cost controls, and operational efficiencies under the Azenta Business System.
Azenta’s non‑GAAP earnings per share of $0.21 beat analyst consensus of $0.19 by $0.02, a 10.5% lift. The beat was largely attributable to the company’s focus on cost discipline, which offset modest revenue growth, and to the favorable product mix that increased the proportion of higher‑margin Multiomics sales.
Management reiterated its fiscal 2026 outlook, projecting core revenue growth of 3%‑5% and an additional 300 basis points of adjusted EBITDA margin expansion. CEO John Marotta said the company had “simplified its organization and strengthened execution, driving measurable improvements in quality, delivery, and productivity.” CFO Lawrence Lin added that Azenta “is in the automated solutions business, not the freezer business,” underscoring a strategic shift toward higher‑margin, integrated solutions.
Investors reacted positively to the earnings, citing the EPS beat and the company’s guidance as key drivers. Azenta will host an Investor Day on December 10, 2025, to outline its multi‑year growth strategy and financial framework.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.